Wide Ranks

ADCT

ADC Therapeutics SA

2.26

Top Statistics
Market Cap 218 M Forward PE -1.52 Revenue Growth 27.40 %
Current Ratio 4.92 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -300.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -2.91 Enterprise / Revenue 5.64 Price To Sales Trailing12 Months 3.09
Profitability
Profit Margins -300.00 % Operating Margins -192.61 %
Balance Sheet
Total Cash 274 M Total Cash Per Share 2.84 Total Debt 454 M
Total Debt To Equity Current Ratio 4.92 Book Value Per Share -1.78
All Measures
Short Ratio 861.00 % Message Board Id finmb_183083930 Shares Short Prior Month 3 M
City Epalinges Uuid fcce8c1b-f218-3d0a-9919-64ee4e1352c8 Previous Close 2.22
First Trade Date Epoch Utc 1 B Book Value -1.78 Beta 1.60
Total Debt 454 M Volume 313898 Fifty Two Week Low 0.8090
Total Cash Per Share 2.84 Total Revenue 70 M Shares Short Previous Month Date 1 B
Target Median Price 8.00 Audit Risk 6 Max Age 86400
Recommendation Mean 1.57 Sand P52 Week Change 0.3133 Operating Margins -192.61 %
Target Mean Price 8.40 Net Income To Common -212150000 Ask 2.49
Short Percent Of Float 0.0468 Implied Shares Outstanding 96 M Last Fiscal Year End 1 B
Trailing Peg Ratio None Average Daily Volume10 Day 474450 Average Volume10days 474450
Total Cash 274 M Next Fiscal Year End 1 B Revenue Per Share 0.7740
Held Percent Insiders 0.2103 Ebitda Margins -193.54 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 1
Regular Market Previous Close 2.22 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.87 Open 2.24 Free Cashflow -96829128
Dividend Yield 0.00 % Return On Assets -0.2117 Time Zone Short Name EST
Board Risk 7 Trailing Eps -2.39 Day Low 2.21
Address1 BiopOle Shares Outstanding 96 M Compensation Risk 8
Price Hint 4 Target High Price 10.00 Website https://www.adctherapeutics.com
52 Week Change 1.72 Average Volume 383982 Forward Eps -1.49
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 440.80 %
Is_sp_500 False Regular Market Day High 2.32 Profit Margins -300.00 %
Fifty Two Week High 6.04 Day High 2.32 Shares Short 3 M
Regular Market Open 2.24 Industry Key biotechnology Bid 2.20
Earnings Growth 0.00 % Enterprise To Revenue 5.64 Revenue Growth 27.40 %
Shares Percent Shares Out 0.0327 Operating Cashflow -133616000 Currency USD
Time Zone Full Name America/New_York Market Cap 218 M Is_nasdaq_100 False
Zip 1066 Quote Type EQUITY Industry Biotechnology
Long Name ADC Therapeutics SA Overall Risk 5 Regular Market Day Low 2.21
Held Percent Institutions 0.6150 Current Price 2.26 Address2 Route de la Corniche 3B
Enterprise To Ebitda -2.91 Financial Currency USD Current Ratio 4.92
Gross Margins -84.64 % Industry Disp Biotechnology Number Of Analyst Opinions 5
Country Switzerland Float Shares 77 M Two Hundred Day Average 3.57
Governance Epoch Date 1 B Enterprise Value 398 M Price To Sales Trailing12 Months 3.09
Forward PE -1.52 Regular Market Volume 313898 Ebitda -136868000
Exchange NYQ
Go to Yahoo Finance Go to Seeking Alpha 
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.

S.

Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.

The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs).

In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia.

Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets.

The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.